Search results for GIP
Industry
Retatrutide shows knee osteoarthritis pain relief in trials
Eli Lilly’s next-generation obesity treatment retatrutide showed effectiveness in weight loss and easing knee osteoarthritis pain in large clinical trials. In two phase 3 studies published in The New England Journal of Medicine, weekly injections produced greater weight reduction and improved pain scores than placebo in overweight or obese adults without type 2 diabetes who also had knee osteoarthritis. Serious adverse events were more frequent than with placebo, with common side effects including nausea and diarrhoea.
Industry
LG Display wins Sejong the Great award with patent cutting bezel by 34 percent
LG Display said on Monday it won the top Sejong the Great award at the 2026 Patent Technology Awards hosted by the Korean Intellectual Property Office for an OLED TV high-integration gate driving circuit patent. The patent redesigns the circuit structure to significantly reduce the bezel and was filed in 2020 in South Korea and in the United States, Germany and China. The company said the technology has improved manufacturing efficiency and delivered 385 billion won in cumulative cost savings.
Industry
Lilly\'s next-generation obesity drug retatrutide shows 25 percent weight loss in 80 weeks
Eli Lilly\'s next-generation obesity drug candidate retatrutide showed an average 25 percent weight loss at the highest dose after 80 weeks in a Phase 3 trial. Among participants who extended treatment to 104 weeks, average weight loss rose to 30 percent. Results were published in the New England Journal of Medicine, with more than one-third losing at least 30 percent of body weight. The study did not directly compare retatrutide with existing obesity drugs, and researchers said further trials are needed.